Clindamycin Capsules bulk supplier for pharma manufacturers

Clindamycin Capsules 75 mg, 150 mg, 300 mg Suppliers & Bulk Manufacturers

Available Forms: Oral Capsules

Available Strengths: 75 mg, 150 mg, 300 mg

Reference Brands: Cleocin (USA), Dalacin C (EU/UK), Clindac (India)

Clindamycin binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and leading to cell death. It effectively treats skin, respiratory, and bone infections. Benefits include broad-spectrum activity, rapid bacterial eradication, and oral convenience, making it a reliable choice for severe bacterial infections when used appropriately.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Clindamycin capsules are widely used antibiotics available in the US and EU, with regulatory approval from agencies like the FDA and EMA. These capsules are included in approved drug dossiers that ensure quality, safety, and efficacy. In the US, brands like Cleocin are FDA-approved, while in the EU, Dalacin C is commonly used. Both regions require rigorous clinical and compliance standards for marketing. For detailed information on regulatory requirements and approved dossiers, visit Pharmatradz. Stay updated on the latest regulations and licensing processes for clindamycin capsules across markets.

Clindamycin Capsules — third party manufacturing & bulk supply

Clindamycin Capsules 75 mg, 150 mg, 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Clindamycin Capsules is supplied as Oral Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Clindamycin Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Clindamycin Capsules →

Back to Listing

Frequently Asked Questions

Clindamycin capsules are used to treat a variety of serious bacterial infections caused by susceptible bacteria. These include infections of the respiratory tract, skin and soft tissues, bone and joints, abdominal infections, dental infections, and certain gynecological infections. Clindamycin works particularly well against anaerobic bacteria and some gram-positive organisms when other antibiotics are not effective or cannot be used.

Clindamycin capsules contain the active pharmaceutical ingredient clindamycin hydrochloride, which belongs to the lincosamide class of antibiotics. It works by inhibiting bacterial protein synthesis, preventing bacteria from growing and multiplying.

Clindamycin capsules are marketed under several trade names worldwide including Cleocin, Dalacin C, and other generic clindamycin capsule brands depending on the manufacturer and region.

One of the well-known brands, Cleocin, was originally developed and marketed by Pfizer. Today, clindamycin capsules are produced by many pharmaceutical companies worldwide including Teva Pharmaceutical Industries, Sandoz, and Viatris along with several other generic manufacturers.

The generic name of Clindamycin Capsules is clindamycin hydrochloride.

Common brand names of Clindamycin Capsules include Cleocin and Dalacin C.

Clindamycin capsules are manufactured in several countries including the United States, India, China, and multiple European countries by different pharmaceutical manufacturers producing both branded and generic versions for global markets.